Literature DB >> 3349482

Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys.

C A Arndt1, F M Balis, C L McCully, O M Colvin, D G Poplack.   

Abstract

The penetration of the active metabolites of cyclophosphamide (CP) and ifosfamide (IF) into cerebrospinal fluid (CSF) was determined in rhesus monkeys following an i.v. infusion of 1 gm/m2 of CP and IF. Active metabolites were measured using a high-performance liquid chromatography assay with fluorometric detection following derivatization with m-aminophenol. CSF to blood ratios of the active metabolites of CP and IF were found to be 0.17 and 0.13 following systemic dosing of CP and IF, respectively. The levels achieved in the CSF, however, were equivalent to levels known to be cytocidal to malignant cell lines derived from tumors which metastasize to the central nervous system. Only one animal demonstrated neurotoxicity with IF. CSF levels of active metabolite in this animal were similar to those observed in the other animals.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3349482

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Epstein-Barr virus and brain lymphomas.

Authors:  R M Bashir; F H Hochberg; M X Wei
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

2.  Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat.

Authors:  S Genka; J Deutsch; P L Stahle; U H Shetty; V John; C Robinson; S I Rapoport; N H Greig
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.

Authors:  Mustafa Aziz Hatiboglu; Ling-Yuan Kong; Jun Wei; Yongtao Wang; Kayla Anne McEnery; Gregory N Fuller; Wei Qiao; Michael A Davies; Waldemar Priebe; Amy B Heimberger
Journal:  Int J Cancer       Date:  2011-08-24       Impact factor: 7.396

Review 4.  Pharmacokinetic considerations in the treatment of CNS tumours.

Authors:  Susannah Motl; Yanli Zhuang; Christopher M Waters; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  In vitro studies on drug interaction of ifosfamide and ACNU in primary and metastatic human brain tumours.

Authors:  U Bogdahn; D Drenkard; M Lutz; R Apfel; C Behl
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

6.  Metabolism and pharmacokinetics of oral and intravenous ifosfamide.

Authors:  V Kurowski; T Cerny; A Küpfer; T Wagner
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

7.  Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

Authors:  S D Baker; R L Heideman; W R Crom; J F Kuttesch; A Gajjar; C F Stewart
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

Review 8.  Ifosfamide clinical pharmacokinetics.

Authors:  T Wagner
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

Review 9.  How to Make Anticancer Drugs Cross the Blood-Brain Barrier to Treat Brain Metastases.

Authors:  Eurydice Angeli; Thuy T Nguyen; Anne Janin; Guilhem Bousquet
Journal:  Int J Mol Sci       Date:  2019-12-18       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.